Myeloma
Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
Blood Cancer TalksBlood Cancer Talks | November 21, 2024
The group discussed four abstracts on belantamab mafodotin in MM presented at EHA 2024 and ASCO 2024.
Leah LawrencePrint | November 18, 2024
The interest in using quantitative tests to measure residual cancer cells continues to expand in the arena of blood cancers.
Melissa BadamoMyeloma | November 14, 2024
A study demonstrated favorable outcomes among high-risk patients with newly diagnosed MM who received HSCT consolidation.
Melissa BadamoMyeloma | November 14, 2024
Cilta-cel plus lenalidomide maintenance provides deep and durable responses with no new safety signals in patients with MM.
Melissa BadamoMyeloma | November 14, 2024
Daratumumab-based induction therapy showed improved responses and comparable safety in newly diagnosed multiple myeloma.
Melissa BadamoMyeloma | November 14, 2024
Adding isatuximab to standard-of-care improved CR and MRD negativity rates in transplant-eligible, newly diagnosed MM.
Advertisement
Andrew MorenoPrint | November 5, 2024
A retrospective study highlighted differences in infection rates and healthcare utilization following CAR-T therapy.
Melissa BadamoMyeloma | November 4, 2024
Mezigdomide, tazemetostat, and dexamethasone demonstrated promising efficacy and safety in relapsed or refractory MM.
Andrew MorenoPrint | November 4, 2024
A phase II trial in patients with at least three prior treatments evaluated two target doses of the CAR T-cell therapy.
Patrick DalyMyeloma | October 31, 2024
This real-world study characterized step-up dosing models for talquetamab in patients with multiple myeloma.
Patrick DalyMyeloma | October 31, 2024
Talquetamab and pomalidomide induced rapid and deep responses in patients with relapsed or refractory multiple myeloma.
Patrick DalyMyeloma | October 31, 2024
The iMMagine-3 randomized trial has begun enrollment of patients with relapsed or refractory multiple myeloma.
Patrick DalyMyeloma | October 31, 2024
OS, infections, hospitalization, and availability off the shelf were preferred treatment attributes of T-cell engagers.
Andrew MorenoPrint | November 4, 2024
The agent is newly approved in polytherapy with bortezomib and dexamethasone for multiple myeloma in adults.
Shebli Atrash, MDMyeloma | October 25, 2024
Dr. Atrash reviews real-world data on four selinexor-based triplets used in the treatment of relapsed or refractory myeloma.
Adriana Rossi, MDMyeloma | October 16, 2024
Drs. Rossi and Khouri discuss two presentations on the effects of selinexor exposure on CAR-T outcomes in multiple myeloma.
Andrew MorenoPrint | November 4, 2024
The agent is a first-of-its-kind, orally available, selective inhibitor of the nuclear export protein exportin 1.
Melissa BadamoMyeloma | October 2, 2024
The new indication for daratumumab and hyaluronidase-fihj plus D-VRd is based on results from the phase II CEPHEUS study.
Julie GouldMyeloma | October 1, 2024
MRD negativity is a strong predictor of better prognosis and survival in patients with MM.
Julie GouldMyeloma | October 1, 2024
Ongoing detection of TP53 mutations remains critical for accurate risk stratification and treatment planning in MM.
Advertisement
Advertisement
Editorial Board